ASCO GU 2019: First-line pembrolizumab shows promise in non-clear cell RCC
The results from the following study were presented at the [...]
ASCO GU 2019: Questions and lessons moving forward from CARMENA: A surgeon’s perspective
The following paper was presented at the American Society for [...]
ASCO GU 2019: When to obtain genetic testing for renal cell carcinoma
The following paper was presented at the American Society for [...]
ASCO GU 2019: Gemcitabine plus axitinib in patients with sarcomatoid renal cell carcinoma (RCC)
Results from this trial for sarcomatoid renal cell carcinoma (RCC) [...]
Immune signature for papillary RCC predicts outcomes
A recent study published in Cancer Medicine has identified immune-related [...]
Potential predictive biomarker of response to VEGF treatment in metastatic kidney cancer
A recent study published on PLOS/ONEÂ has identified three genetic mutations/alterations [...]
Nivolumab plus ipilimumab combination shows survival benefit for patients with untreated kidney cancer at 30 months
Further survival data has been released from the phase 3 [...]
First-line cabozantinib declined for a second time for use within NHS Scotland
Cabozantinib has been declined for a second time by the [...]
Four distinct subgroups of clear cell renal cancer identified
Using gene profiling, a recent study published in Cancer Discovery [...]
Incidence of some obesity-related cancers in increasing in younger people
A recent study, published in The Lancet Public Health, has [...]
